Abstract
The complete remission (CR) rate achieved with induction chemotherapy prior to autologous stem cell transplantation (ASCT) represents the strongest prognostic factor in relapsed/ refractory (R/R) classical Hodgkin lymphoma (cHL). By inducing a CR rate of 75%, the bendamustine, gemcitabine, vinorelbine (BEGEV) regimen represents an optimal chemotherapy regimen prior to ASCT. Presented here are the 5-year results of BEGEV followed by ASCT in R/R cHL. With a median follow-up of 5 years, progression-free survival (PFS) and overall survival (OS) for the whole series (n 5 59) were 59% and 78%, respectively. ASCT was performed in 43 of 49 responding patients (73% by intention to treat [ITT]; 88% by response to BEGEV) and resulted in 33 with continuous CR (56% by ITT; 77% of transplanted patients), 7 with disease relapse, and 3 with nonrelapse mortality. For patients who received transplants, the 5-year PFS and OS were 77% and 91%, respectively, with no significant difference between relapsed and refractory patients. No patient experienced secondary leukemia or myelodysplasia. In summary, the long-term efficacy data, the benefits for both relapsed and refractory patients, and the excellent safety profile provide a strong rationale for further development of the BEGEV regimen. © 2020 by The American Society of Hematology.
Original language | English |
---|---|
Pages (from-to) | 136-140 |
Number of pages | 5 |
Journal | Blood Adv. |
Volume | 4 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- bendamustine
- gemcitabine
- vinorelbine tartrate
- Article
- autologous stem cell transplantation
- cancer combination chemotherapy
- cancer mortality
- cancer recurrence
- cancer survival
- classical Hodgkin lymphoma
- drug efficacy
- drug safety
- female
- follow up
- human
- leukemia relapse
- long term care
- major clinical study
- male
- multiple cycle treatment
- outcome assessment
- overall survival
- priority journal
- progression free survival
- risk benefit analysis
- salvage therapy
- survival time
- treatment duration